AOD-9604 vs MOTS-c vs Tesamorelin vs Semaglutide vs Tirzepatide: Mechanisms, Benefits, and Key Differences Weight loss medicine has evolved dramatically over the past decade
peaks during dose escalation, typically mild-moderate Diarrhea -- 10-20%, usually transient Constipation -- 8-15% Vomiting -- 5-15%, more frequent at higher doses Injection site reactions -- 5-10%, mild erythema and pruritus Decreased appetite -- 5-12%, related to mechanism of action Pancreatitis -- rare but monitored (as with all GLP-1/amylin agents) Gallbladder events -- cholelithiasis reported, consistent with rapid weight loss Trial data describes dose titration as central to tolerability -- the 16-week escalation protocol substantially reduced GI adverse events
Potential benefits of using GLP-1 receptor agonists after gastric sleeve surgery include: Enhanced weight loss : Observational studies suggest post-bariatric patients using GLP-1 receptor agonists may achieve additional weight reduction, typically around 510% of body weight, though individual responses vary considerably Improved glycaemic control : Particularly beneficial for patients with type 2 diabetes or prediabetes, as GLP-1 agonists enhance insulin secretion and reduce blood glucose levels Reduced appetite : These medications can help patients who struggle with persistent hunger despite surgical intervention Cardiovascular benefits : Semaglutide has demonstrated cardiovascular risk reduction in people with established cardiovascular disease, which may benefit eligible post-bariatric patients with this specific risk profile Maintenance of weight loss : May help prevent weight regain during the critical maintenance phase Potential risks and considerations include: Gastrointestinal side effects : Nausea, vomiting, diarrhoea, and constipation are common, particularly during dose escalation
You never eyeball millilitres on an insulin syringe you read units
writingreview and editing: S.B.A., M.M., M.B.F., and N.I.M.F
